Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
Stephen
S
Salloway
Reisa
R
Sperling
H Robert
HR
Brashear
D000544:Alzheimer Disease / Q000188:drug therapy*; D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male
D016229:Amyloid beta-Peptides; D061067:Antibodies, Monoclonal, Humanized